Clinical Care

Access to Alzheimer’s disease diagnostic biomarkers in clinical routine

A future scenario: digital and blood biomarkers for Alzheimer’s disease diagnosis in primary care

Current and future role of tau-PET in dementia daily practice

Lecanemab vs aducanumab

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Primary care digital screening tool for Alzheimer’s disease

Remaining challenges in bringing fluid biomarkers into clinical practice

Bringing the pTau/Aβ42 biomarker into the clinic

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI

The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

Ageism in the healthcare system

Poor outcomes in delirium superimposed on dementia

Early predictive value of plasma biomarkers for amyloid positivity

Apathy in dementia

Blood biomarkers in Alzheimer’s disease: appropriate use recommendations

Quantifying brain health and identifying ADRD risk factors with the Brain Health Platform